Celgene Corporation (CELG) – Bull of the Day
Source: http://www.zacks.com/commentary/9632/Celgene+Corporation+%28CELG%29+-+Bull+of+the+DayPosted on Wednesday, December 31st, 2008 | In Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
Celgene Corp. (CELG) is a fully integrated biotechnology company focused on discovery, development and commercialization of drugs in the area of cancer and immune/inflammatory diseases.
The acquisition of Pharmion brings three medically meaningful products — Thalomid, Revlimid and Vidaza — into market, which will drive growth in 2009 and beyond. The myelodysplastic syndrome (MDS) market will be dominated by Celgene with complementary Vidaza and Revlimid, although Revlimid and Thalomid face tough competition in the multiple myeloma (MM) market.
Also, its strong balance sheet and deep pipeline will provide long-term growth for the company. Our price target is $70.
“CELG” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Tags for this Post:
Biotechnology, cancer, Celgene Corporation, Day Celgene Corp.;, integrated biotechnology;, meaningful products;, multiple myeloma, myelodysplastic syndrome;, Pharmion, Revlimid;, Stocks to Watch, Thalomid;, USD, Vidaza;, Zacks Market Commentaries
Biotechnology, cancer, Celgene Corporation, Day Celgene Corp.;, integrated biotechnology;, meaningful products;, multiple myeloma, myelodysplastic syndrome;, Pharmion, Revlimid;, Stocks to Watch, Thalomid;, USD, Vidaza;, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.